26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: Real-world results

Background: We compared patients’ adherence, persistence, and monotherapy duration for ixekizumab, an IL-17A inhibitor, vs secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years using real-world data.